The progression of many human
neurodegenerative disorders is associated with an accumulation of
alpha-synuclein.
Alpha-synuclein belongs to the homologous
synuclein family, which includes
beta-synuclein. It has been proposed that
beta-synuclein may be a natural regulator of
alpha-synuclein. Therefore controlling
beta-synuclein expression may control the accumulation of
alpha-synuclein and ultimately prevent
disease progression. The regulation of
synucleins is poorly understood. We investigated the transcriptional regulation of
beta-synuclein, with the aim of identifying molecules that differentially control
beta-synuclein expression levels. To investigate transcriptional regulation of
beta-synuclein, we used reporter gene assays and bioinformatics. We identified a region -1.1/-0.6 kb upstream of the
beta-synuclein translational start site to be a key regulatory region of
beta-synuclein 5'-promoter activity in human dopaminergic cells (SH-SY5Y). Within this key promoter region we identified a
metal response element pertaining to a putative
Metal Transcription Factor-1 (MTF-1) binding site. We demonstrated that MTF-1 binds to this 5'-promoter region using EMSA analysis. Moreover, we showed that MTF-1 differentially regulates
beta-synuclein promoter binding site, as well as
beta-synuclein mRNA and
protein expression. This effect of MTF-1 on expression was found to be specific to
beta-synuclein when compared to
alpha-synuclein. Understanding the regulation of
synucleins and how they interact may point to molecular targets that could be manipulated for therapeutic benefit. In this study we showed that MTF-1 differentially controls the expression of
beta-synuclein when compared to its homolog
alpha-synuclein. This could potentially provide a novel targets or pathways for therapeutic intervention and/or treatment of
synucleinopathies.